ABUS vs DOV · P/E 5.4, rev $6.2M vs P/E 27, rev $7.75B
Arbutus Biopharma Corp (ABUS) versus Dover Corporation (DOV) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Dover Corporation (DOV) is a specialty industrial machinery company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported DOV revenue for 2024-12-31 was $7.75B. Net income was $2.70B. Revenue was up 0.8% from 2023-12-31 to 2024-12-31. DOV currently screens at market cap $28.92B and trailing P/E 26.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. DOV currently screens at market cap $28.92B and trailing P/E 26.8.
Not investment advice. Open the ABUS and DOV stock pages for the full models.
Not investment advice.